客座编辑评论：了解新型药物时代多发性骨髓瘤的发病机制及不断演变的治疗模式。 - Suppr

Suppr

超能文献

Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents.

作者信息

Abe Masahiro

机构信息

University of Tokushima, Tokushima, Japan.

出版信息

Int J Hematol. 2011 Oct;94(4):307-309. doi: 10.1007/s12185-011-0950-4. Epub 2011 Oct 13.

DOI:10.1007/s12185-011-0950-4

PMID:21993876

Abstract

摘要

相似文献

Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents.

Int J Hematol. 2011 Oct;94(4):307-309. doi: 10.1007/s12185-011-0950-4. Epub 2011 Oct 13.

[Multiple myeloma. Diagnosis and therapy].

Internist (Berl). 2003 May;44(5):599-600, 603-16; quiz 617-8. doi: 10.1007/s00108-003-0920-x.

Current concepts of clinical management of multiple myeloma.

Dis Mon. 2012 Apr;58(4):195-207. doi: 10.1016/j.disamonth.2012.01.006.

How to Think About Risk in Myeloma.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S135-8. doi: 10.1016/j.clml.2016.02.015.

[Multiple myeloma].

Praxis (Bern 1994). 2012 Jun 20;101(13):857-61. doi: 10.1024/1661-8157/a000986.

The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.

Blood Rev. 2019 Mar;34:56-66. doi: 10.1016/j.blre.2018.11.003. Epub 2018 Nov 23.

Myeloma bone disease: pathogenesis and treatment.

Oncology (Williston Park). 2005 Jul;19(8):983-4, 986.

[Physiopathology, diagnosis and therapy in multiple myeloma (discussion)].

Nihon Naika Gakkai Zasshi. 1995 Jul 10;84(7):1132-49.

[Multiple Myeloma].

Gan To Kagaku Ryoho. 2014 May;41(5):580-6.

Multiple myeloma.

Hematology Am Soc Hematol Educ Program. 2002:214-40. doi: 10.1182/asheducation-2002.1.214.

引用本文的文献

Heme Oxygenase-1 Overexpression Promotes Uveal Melanoma Progression and Is Associated with Poor Clinical Outcomes.

Antioxidants (Basel). 2022 Oct 8;11(10):1997. doi: 10.3390/antiox11101997.

Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells.

Mol Neurobiol. 2018 Apr;55(4):3344-3350. doi: 10.1007/s12035-017-0575-6. Epub 2017 May 11.

The non-canonical functions of the heme oxygenases.

Oncotarget. 2016 Oct 18;7(42):69075-69086. doi: 10.18632/oncotarget.11923.

Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.

Oncotarget. 2016 May 17;7(20):28868-80. doi: 10.18632/oncotarget.7563.

本文引用的文献

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.

Blood. 2011 Oct 20;118(16):4359-62. doi: 10.1182/blood-2011-03-342089. Epub 2011 Aug 22.

Targeting bone as a therapy for myeloma.

Cancer Microenviron. 2011 Dec;4(3):299-311. doi: 10.1007/s12307-011-0079-2. Epub 2011 Aug 11.

The microenvironment and molecular biology of the multiple myeloma tumor.

Adv Cancer Res. 2011;110:19-42. doi: 10.1016/B978-0-12-386469-7.00002-5.

Advances in the biology and treatment of bone disease in multiple myeloma.

Clin Cancer Res. 2011 Mar 15;17(6):1278-86. doi: 10.1158/1078-0432.CCR-10-1804.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925.

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Expert Rev Hematol. 2011 Feb;4(1):51-60. doi: 10.1586/ehm.10.83.

Management of older patients with multiple myeloma.

Blood Rev. 2011 Mar;25(2):65-73. doi: 10.1016/j.blre.2010.10.003. Epub 2011 Feb 4.

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.

Cancer. 2011 Mar 1;117(5):1001-9. doi: 10.1002/cncr.25535. Epub 2010 Oct 13.

Tumor-host cell interactions in the bone disease of myeloma.

Bone. 2011 Jan;48(1):121-8. doi: 10.1016/j.bone.2010.06.029. Epub 2010 Jul 13.

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

Blood. 2010 Oct 7;116(14):2543-53. doi: 10.1182/blood-2009-12-261032. Epub 2010 Jun 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents.

Int J Hematol. 2011 Oct;94(4):307-309. doi: 10.1007/s12185-011-0950-4. Epub 2011 Oct 13.

[Multiple myeloma. Diagnosis and therapy].

Internist (Berl). 2003 May;44(5):599-600, 603-16; quiz 617-8. doi: 10.1007/s00108-003-0920-x.

Current concepts of clinical management of multiple myeloma.

Dis Mon. 2012 Apr;58(4):195-207. doi: 10.1016/j.disamonth.2012.01.006.

How to Think About Risk in Myeloma.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S135-8. doi: 10.1016/j.clml.2016.02.015.

[Multiple myeloma].

Praxis (Bern 1994). 2012 Jun 20;101(13):857-61. doi: 10.1024/1661-8157/a000986.

The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.

Blood Rev. 2019 Mar;34:56-66. doi: 10.1016/j.blre.2018.11.003. Epub 2018 Nov 23.

Myeloma bone disease: pathogenesis and treatment.

Oncology (Williston Park). 2005 Jul;19(8):983-4, 986.

[Physiopathology, diagnosis and therapy in multiple myeloma (discussion)].

Nihon Naika Gakkai Zasshi. 1995 Jul 10;84(7):1132-49.

[Multiple Myeloma].

Gan To Kagaku Ryoho. 2014 May;41(5):580-6.

Multiple myeloma.

Hematology Am Soc Hematol Educ Program. 2002:214-40. doi: 10.1182/asheducation-2002.1.214.

引用本文的文献

Heme Oxygenase-1 Overexpression Promotes Uveal Melanoma Progression and Is Associated with Poor Clinical Outcomes.

Antioxidants (Basel). 2022 Oct 8;11(10):1997. doi: 10.3390/antiox11101997.

Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells.

Mol Neurobiol. 2018 Apr;55(4):3344-3350. doi: 10.1007/s12035-017-0575-6. Epub 2017 May 11.

The non-canonical functions of the heme oxygenases.

Oncotarget. 2016 Oct 18;7(42):69075-69086. doi: 10.18632/oncotarget.11923.

Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.

Oncotarget. 2016 May 17;7(20):28868-80. doi: 10.18632/oncotarget.7563.

本文引用的文献

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.

Blood. 2011 Oct 20;118(16):4359-62. doi: 10.1182/blood-2011-03-342089. Epub 2011 Aug 22.

Targeting bone as a therapy for myeloma.

Cancer Microenviron. 2011 Dec;4(3):299-311. doi: 10.1007/s12307-011-0079-2. Epub 2011 Aug 11.

The microenvironment and molecular biology of the multiple myeloma tumor.

Adv Cancer Res. 2011;110:19-42. doi: 10.1016/B978-0-12-386469-7.00002-5.

Advances in the biology and treatment of bone disease in multiple myeloma.

Clin Cancer Res. 2011 Mar 15;17(6):1278-86. doi: 10.1158/1078-0432.CCR-10-1804.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925.

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Expert Rev Hematol. 2011 Feb;4(1):51-60. doi: 10.1586/ehm.10.83.

Management of older patients with multiple myeloma.

Blood Rev. 2011 Mar;25(2):65-73. doi: 10.1016/j.blre.2010.10.003. Epub 2011 Feb 4.

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.

Cancer. 2011 Mar 1;117(5):1001-9. doi: 10.1002/cncr.25535. Epub 2010 Oct 13.

Tumor-host cell interactions in the bone disease of myeloma.

Bone. 2011 Jan;48(1):121-8. doi: 10.1016/j.bone.2010.06.029. Epub 2010 Jul 13.

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

Blood. 2010 Oct 7;116(14):2543-53. doi: 10.1182/blood-2009-12-261032. Epub 2010 Jun 23.